media – Page 546 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

FDA Approves Hizentra® (Immune Globulin Subcutaneous 20% Liquid) for the Treatment of Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

First and only subcutaneous immunoglobulin (SCIg) approved for the treatment of CIDP based on the largest controlled clinical study in CIDP
- Source: finance.yahoo
- 689
- March 20, 2018
CIDP FDA Hizentra® New Approvals
Study highlights how EHR data can pinpoint undiagnosed genetic diseases

A new study out of Vanderbilt University Medical Center found genetic data in electronic health records can be used to spot undiagnosed diseases.
- Source: MedCity News
- 599
- March 20, 2018
EHR healthcare technologies and innovations medtech Researches
Implantable sensor relays real-time personal health data to a cell phone

Personalized medicine is one step closer for consumers, thanks to tiny, implantable sensors that could give an early warning of a person's developing health problems, indicate the most effective type of exercise for an individual athlete, or even help triage wounded soldiers. That's the vision for a family of devices that scientists are now developing. They have begun marketing their first device in Europe and hope to win approval for this technology in the U.S.
- Source: TechExplore
- 552
- March 20, 2018
digital health healthcare technologies and innovations New Approvals
Paraplegic Rat Walks Again After Therapy

Using electrochemical stimulation and robot-assisted rehabilitation techniques, researchers restore walking ability in a paraplegic rat. The study reports reorganization of neural branching in the reticular formation leads to new connections and is key to motor skill recovery.
- Source: NeuroScience News
- 519
- March 20, 2018
rehabilitation Researches spinal cord
Blockchain medical device set to improve the delivery for babies born by C-section

NnBu Holdings has developed a blockchain medical device to help deliver healthy outcomes for babies born by C-section.
- Source: Open Access Government
- 662
- March 19, 2018
blockchain digital health Researches
Abeona Therapeutics Receives FDA Rare Pediatric Disease Designation for ABO-202 Gene Therapy Program in CLN1 Disease

Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, announced today that the FDA has granted Rare Pediatric Disease Designation for the ABO-202 program (AAV-CLN1), an AAV-based gene therapy for the treatment of CLN1 disease (infantile and late infantile onset Batten disease).
- Source: Tmcnet
- 433
- March 19, 2018
CLN1 disease lysosomal storage New Approvals
Autism’s social deficits are reversed by an anti-cancer drug

Using an epigenetic mechanism, romidepsin restored gene expression and alleviated social deficits in animal models of autism
- Source: Sciencedaily
- 502
- March 19, 2018
autism Researches romidepsin
Artificial Intelligence powers new lung health app

Aseptika in St Ives and Zenzium in Cheshire have been awarded an unspecified grant from the UK’s innovation agency to leverage AI and develop a new home-based early warning system for people with severe respiratory disease.
- Source: Business Weekly
- 622
- March 19, 2018
AI COPD Researches respiratory
Bellicum Announces Interim Results Showing Low Rates of Cancer Recurrence in Pediatric AML Patients Treated with BPX-501

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today reported interim clinical data of BPX-501 in pediatric patients with acute myeloid leukemia (AML) and primary immunodeficiencies (PIDs). BPX-501 is an adjunct T cell therapy incorporating CaspaCIDe® administered after haploidentical hematopoietic stem cell transplant (haplo-HSCT) for the treatment of hematologic cancers and inherited blood diseases.
- Source: ir.bellicum
- 553
- March 19, 2018
AML BPX-501 Clinical Trials PIDs T cell therapy
Janssen Announces U.S. FDA Breakthrough Therapy Designation for Erdafitinib in the Treatment of Metastatic Urothelial Cancer

Erdafitinib, an oral pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, shows promise as the first targeted agent for patients with metastatic urothelial cancer, one of the most common cancers
- Source: janssen
- 620
- March 19, 2018
erdafitinib FDA Janssen Johnson & Johnson

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.